Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bilastine + levocetirizine
- Development stage
- Unknown
- Lead developer
- Faes Farma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Bilastine + levocetirizine is a combination therapy consisting of two second-generation H1-antihistamines, currently being evaluated by Derma Techno Pakistan for the treatment of chronic spontaneous urticaria (CSU). Bilastine is a highly selective peripheral H1-receptor antagonist known for its non-sedating properties and lack of hepatic metabolism. Levocetirizine is the active R-enantiomer of cetirizine and serves as a potent, selective H1-receptor antagonist. This combination is typically utilized in clinical practice for patients who remain symptomatic despite standard antihistamine monotherapy. The rationale for the combination is to achieve superior control of pruritus and wheals through additive antihistaminic effects. In clinical trials, this regimen is often compared against up-dosed bilastine monotherapy to determine the most effective and safe approach for managing treatment-resistant CSU.
- Other names
- bilastine and levocetirizine combinationbilastine plus levocetirizine
02
Targets
HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on bilastine + levocetirizine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bilastine + levocetirizine.